IDEXX Beats on Q3 Revenue, Raises Full-Year EPS Outlook to $14.96-$15.16
IDXX is trading near its 52-week low of $500.61 (11% above the low) on elevated volume (2.2× avg).
Summary
Q3 revenue rose 10% to $1.21 billion, topping the $1.19 billion consensus, and EPS climbed 18% to $4.01. The bigger news is guidance: IDEXX lifted its 2026 revenue outlook to $4.74-$4.77 billion (up $32 million at the midpoint) and raised EPS guidance to $14.96-$15.16, $0.25 higher at the midpoint. That offsets a trimmed operating margin outlook of 32.1%-32.3%, down from 32.3%-32.5%. Growth came from double-digit recurring diagnostics revenue on same-store volume and customer gains, plus new analyzers and price realization. This follows the Q2 print in August that also beat and raised, so the beat-and-raise pattern is holding.
At the time of this announcement, IDXX was trading at $555.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.4B. The 52-week trading range was $500.61 to $769.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.